DEF: Alkermes Sets Date for 2025 Annual General Meeting, Outlines Key Proposals

Alkermes plc will hold its 2025 Annual General Meeting on May 21, 2025, to vote on director elections, executive compensation, auditor ratification, and stock plan approval.

Summary

• Alkermes plc will hold its 2025 Annual General Meeting of Shareholders on May 21, 2025, in Dublin, Ireland.
• Shareholders will vote on the election of nine director nominees for a one-year term.
• A non-binding advisory vote will be held on the compensation of the company's named executive officers.
• Shareholders will ratify the appointment of PricewaterhouseCoopers LLP as the independent auditor and authorize the Audit and Risk Committee to set the auditor's remuneration.
• The meeting will include a vote to approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended, increasing the share authorization by 4,250,000 shares.
• The board is seeking renewal of its authority to allot and issue shares under Irish law, up to 20% of the issued share capital as of April 1, 2025.
• The board is also seeking renewal of its authority to disapply statutory pre-emption rights under Irish law, up to 20% of the issued share capital as of April 1, 2025.
• The record date for the Annual Meeting is March 14, 2025.
• Alkermes generated revenues greater than $1.5 billion in 2024, driven by its proprietary commercial portfolio.
• The company completed the sale of its manufacturing business in Ireland and repurchased approximately 8 million ordinary shares.
• Alkermes retired all of its debt and ended the year with approximately $825 million in cash.
• The company significantly advanced its neuroscience development pipeline, including ALKS 2680.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Alkermes, highlighting strong financial performance, pipeline advancements, and commitment to corporate responsibility. The tone is optimistic and confident, suggesting a favorable sentiment.

Positives

• Alkermes generated revenues greater than $1.5 billion in 2024.
• The company completed the sale of its manufacturing business in Ireland, streamlining its manufacturing footprint.
• Alkermes drove robust profitability, yielding more than $450 million of EBITDA from continuing operations.
• The company repurchased approximately 8 million of its ordinary shares, retired all of its debt, and ended the year with approximately $825 million of cash.
• Alkermes significantly advanced its neuroscience development pipeline, including ALKS 2680.
• The company delivered strong total shareholder returns through December 31, 2024.
• Alkermes published its seventh annual Corporate Responsibility Report.
• The company has entered 2025 well-positioned to execute on its strategy, with a strong balance sheet and a substantial commercial business.

Future Outlook

Alkermes is well-positioned to execute on its strategy in 2025, with a strong balance sheet, a substantial commercial business, and a commitment to continued operational efficiency and profitability, while continuing to invest in growth opportunities.

Management Comments

• 2024 was a year of significant progress for Alkermes, marked by commercial execution, efficiency and profitability, and advancement and expansion of our pipeline.
• We have entered 2025 well-positioned to execute on our strategy, with a strong balance sheet, a substantial commercial business and a commitment to continued operational efficiency and profitability, while continuing to invest in the growth opportunities that we believe will be the key drivers of shareholder value.

Industry Context

The announcement reflects Alkermes' focus on neuroscience and its efforts to compete in the biopharmaceutical industry through commercial execution, pipeline development, and financial discipline.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention that the company benchmarks its executive compensation against a peer group of comparable companies.
• The document also mentions that the company strives to maintain rates of workplace accidents resulting in recordable injuries, and of accidents resulting in lost employee work time, below U.S. Bureau of Labor Statistics industry averages in 2024.
• The document also mentions that Alkermes was certified as a Great Place to Work in the United States , named to Fortune Magazines Best Workplaces in BioPharma 2024 and, for the third consecutive year, awarded the Platinum Bell Seal for Workplace Mental Health , presented by Mental Health America.

Stakeholder Impact

• Shareholders: The company's performance and strategic initiatives are expected to drive long-term value.
• Employees: The company is committed to fostering an inclusive and collaborative workplace.
• Patients: The company is focused on developing innovative medicines to address unmet needs in neuroscience.
• Customers: The company is committed to providing high-quality products and services.
• Communities: The company is committed to operating in a sustainable and responsible manner.

Next Steps

• Shareholders to vote on proposals at the Annual General Meeting on May 21, 2025.
• The company will continue to execute on its strategy, focusing on commercial growth, pipeline advancement, and operational efficiency.
• The company will continue to engage with shareholders and other stakeholders on a regular basis.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, Director Elections, Executive Compensation, Auditor Ratification, Stock Option Plan, Share Issuance, Pre-emption Rights, Financial Performance, Neuroscience Pipeline, ALKS 2680, VIVITROL, LYBALVI, ARISTADA, Alkermes